BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-3783. [PMID: 15365074 DOI: 10.1200/jco.2004.12.082] [Cited by in Crossref: 400] [Cited by in F6Publishing: 184] [Article Influence: 22.2] [Reference Citation Analysis]
Number Citing Articles
1 Calvo F, Guillen Ponce C, Muñoz Beltran M, Sanjuanbenito Dehesa A. Multidisciplinary management of locally advanced–borderline resectable adenocarcinoma of the head of the pancreas. Clin Transl Oncol 2013;15:173-81. [DOI: 10.1007/s12094-012-0962-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
2 Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
3 Chen J, Chen L, Yu J, Xu Y, Wang X, Zeng Z, Liu N, Xu F, Yang S. Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities. Mol Med Rep 2019;19:477-89. [PMID: 30431091 DOI: 10.3892/mmr.2018.9638] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci 2017;18:E909. [PMID: 28445400 DOI: 10.3390/ijms18050909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
5 Lee JJ, Huang J, England CG, McNally LR, Frieboes HB. Predictive modeling of in vivo response to gemcitabine in pancreatic cancer. PLoS Comput Biol 2013;9:e1003231. [PMID: 24068909 DOI: 10.1371/journal.pcbi.1003231] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
6 Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Mol Ther Oncolytics 2019;12:56-67. [PMID: 30705966 DOI: 10.1016/j.omto.2018.12.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
7 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 473] [Article Influence: 53.2] [Reference Citation Analysis]
8 van Rijssen LB, Narwade P, van Huijgevoort NC, Tseng DS, van Santvoort HC, Molenaar IQ, van Laarhoven HW, van Eijck CH, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group. Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis. HPB (Oxford) 2016;18:559-66. [PMID: 27346135 DOI: 10.1016/j.hpb.2016.05.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
9 Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
10 Giovinazzo F, Soggiu F, Jang JY, Versteijne E, van Tienhoven G, van Eijck CH, Han Y, Choi SH, Kang CM, Zalupski M, Ahmad H, Yentz S, Helton S, Rose JB, Takishita C, Nagakawa Y, Abu Hilal M. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.Front Oncol. 2020;10:1112. [PMID: 32850319 DOI: 10.3389/fonc.2020.01112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 2010;12:223-32. [PMID: 20198462 DOI: 10.1208/s12248-010-9181-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 5.7] [Reference Citation Analysis]
12 Epelbaum R, Shacham-Shmueli E, Klein B, Agbarya A, Brenner B, Brenner R, Gez E, Golan T, Hubert A, Purim O, Temper M, Tepper E, Voss A, Russell K, Dvir A, Soussan-Gutman L, Stemmer SM, Geva R. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. Biomed Res Int 2015;2015:681653. [PMID: 26161408 DOI: 10.1155/2015/681653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Okamoto Y, Maeba T, Kakinoki K, Okano K, Izuishi K, Wakabayashi H, Usuki H, Suzuki Y. A patient with unresectable advanced pancreatic cancer achieving long-term survival with gemcitabine chemotherapy. World J Gastroenterol. 2008;14:6876-6880. [PMID: 19058319 DOI: 10.3748/wjg.14.6876] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Han B, Kim BJ, Kim HS, Choi DR, Shim BY, Lee KH, Kim JW, Kim JH, Song H, Kim JH, Park CK, Lee JW, Kim MJ, Zang DY. A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. J Cancer 2021;12:912-7. [PMID: 33403047 DOI: 10.7150/jca.50514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009;27:5506-5512. [PMID: 19858396 DOI: 10.1200/jco.2009.22.1309] [Cited by in Crossref: 58] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
16 Kindler HL. Pancreatic cancer: an update. Curr Oncol Rep 2007;9:170-6. [PMID: 17430687 DOI: 10.1007/s11912-007-0018-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
17 Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther 2010;3:111-27. [PMID: 20856847 DOI: 10.2147/ott.s7203] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
18 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
19 Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622. [PMID: 20606091 DOI: 10.1200/jco.2010.28.1386] [Cited by in Crossref: 562] [Cited by in F6Publishing: 331] [Article Influence: 46.8] [Reference Citation Analysis]
21 Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J, Buchsbaum D. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Mol Cancer Ther. 2016;15:680-688. [PMID: 26832793 DOI: 10.1158/1535-7163.mct-15-0764] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
22 Li K, Yang J, Chen J, Shi Y, Zhang Z, Chen W. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. Oncol Lett 2020;19:1584-92. [PMID: 31966084 DOI: 10.3892/ol.2019.11205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Cohen SJ, Zalupski MM, Modiano MR, Conkling P, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemother Pharmacol 2010;66:287-94. [PMID: 19855966 DOI: 10.1007/s00280-009-1162-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
24 Cui J, Yang H, Liu J, Chen D, Hu J, Zhang H, Wang Y, Han T, Mao T, Jiao F, Biskup E, Pan Y, Liu M, Wang L. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer 2021;21:672. [PMID: 34098895 DOI: 10.1186/s12885-021-08375-6] [Reference Citation Analysis]
25 Isacoff WH, Reber HA, Bedford R, Hoos W, Rahib L, Upfill-Brown A, Donahue T, Hines OJ. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Target Oncol 2018;13:461-8. [PMID: 29882102 DOI: 10.1007/s11523-018-0572-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
26 Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2784-2796. [PMID: 27247222 DOI: 10.1200/jco.2016.67.1412] [Cited by in Crossref: 166] [Cited by in F6Publishing: 90] [Article Influence: 27.7] [Reference Citation Analysis]
27 Momi N, Kaur S, Ponnusamy MP, Kumar S, Wittel UA, Batra SK. Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis. Carcinogenesis 2012;33:1617-28. [PMID: 22623649 DOI: 10.1093/carcin/bgs186] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
28 Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27:193-198. [PMID: 19047305 DOI: 10.1200/jco.2008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Ozaki T, Yu M, Yin D, Sun D, Zhu Y, Bu Y, Sang M. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations. BMC Cancer 2018;18:309. [PMID: 29558908 DOI: 10.1186/s12885-018-4217-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
30 Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther. 2013;7:33-43. [PMID: 24379681 DOI: 10.2147/ott.s38111] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
31 Spano JP, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs 2012;30:1531-9. [PMID: 21670972 DOI: 10.1007/s10637-011-9697-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
32 Lamb YN, Scott LJ. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. Drugs 2017;77:785-92. [PMID: 28401446 DOI: 10.1007/s40265-017-0741-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
33 Schultheis B, Strumberg D, Bergmann L, Graeven U, Hanauske AR, Lipp R, Schuette J, Saito K, Scigalla P, Scheulen ME. Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). Invest New Drugs. 2012;30:1184-1192. [PMID: 21484249 DOI: 10.1007/s10637-011-9665-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
34 Yang ZY, Yuan JQ, Di MY, Zheng DY, Chen JZ, Ding H, Wu XY, Huang YF, Mao C, Tang JL. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013;8:e57528. [PMID: 23472089 DOI: 10.1371/journal.pone.0057528] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
35 Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JL. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 2006;24:515-20. [PMID: 16699973 DOI: 10.1007/s10637-006-8440-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
36 Ben-Josef E, Lawrence TS. Chemoradiotherapy for unresectable pancreatic cancer. Int J Clin Oncol 2008;13:121-6. [PMID: 18463955 DOI: 10.1007/s10147-007-0763-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
37 Au M, Emeto TI, Power J, Vangaveti VN, Lai HC. Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials. Biomedicines 2016;4:E20. [PMID: 28536387 DOI: 10.3390/biomedicines4030020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
38 Urrutia G, Salmonson A, Toro-Zapata J, de Assuncao TM, Mathison A, Dusetti N, Iovanna J, Urrutia R, Lomberk G. Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse. Mol Cancer Res 2020;18:448-62. [PMID: 31822519 DOI: 10.1158/1541-7786.MCR-19-0490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
39 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
40 Yin S, Xu L, Bandyopadhyay S, Sethi S, Reddy KB. Cisplatin and TRAIL enhance breast cancer stem cell death. Int J Oncol. 2011;39:891-898. [PMID: 21687939 DOI: 10.3892/ijo.2011.1085] [Cited by in Crossref: 5] [Cited by in F6Publishing: 23] [Article Influence: 0.5] [Reference Citation Analysis]
41 Rombouts S, Walma M, Vogel JA, Rijssen Lv, Wilmink J, Mohammad NH, Santvoort Hv, Molenaar IQ, Besselink MG Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. American Society of Clinical Oncology Annual Meeting. 2016;suppl: abstr 4115. [PMID: 27370653 DOI: 10.1245/s10434-016-5373-2] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 13.2] [Reference Citation Analysis]
42 Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006;95:587-592. [PMID: 16909140 DOI: 10.1038/sj.bjc.6603301] [Cited by in Crossref: 140] [Cited by in F6Publishing: 145] [Article Influence: 8.8] [Reference Citation Analysis]
43 Awasthi N, Schwarz MA, Schwarz RE. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB (Oxford) 2011;13:597-604. [PMID: 21843259 DOI: 10.1111/j.1477-2574.2011.00333.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
44 Kang CM, Babicky ML, Lowy AM. The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas. 2014;43:183-189. [PMID: 24518495 DOI: 10.1097/mpa.0000000000000088] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
45 Ren X, Zhao W, Du Y, Zhang T, You L, Zhao Y. Activator protein 1 promotes gemcitabine-induced apoptosis in pancreatic cancer by upregulating its downstream target Bim. Oncol Lett 2016;12:4732-8. [PMID: 28105181 DOI: 10.3892/ol.2016.5294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
46 Banu E, Banu A, Fodor A, Landi B, Rougier P, Chatellier G, Andrieu JM, Oudard S. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging. 2007;24:865-879. [PMID: 17896834 DOI: 10.2165/00002512-200724100-00006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
47 Choi JG, Seo JH, Oh SC, Choi CW, Kim JS. A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. Cancer Res Treat. 2012;44:127-132. [PMID: 22802751 DOI: 10.4143/crt.2012.44.2.127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
48 Ghosn M, Kourie HR, Karak FE, Hanna C, Antoun J, Nasr D. Optimum chemotherapy in the management of metastatic pancreatic cancer. World J Gastroenterol 2014; 20(9): 2352-2357 [PMID: 24605032 DOI: 10.3748/wjg.v20.i9.2352] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
49 Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med 2013;11:291. [PMID: 24237633 DOI: 10.1186/1479-5876-11-291] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
50 Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J 3rd, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer 2009;100:1842-5. [PMID: 19491904 DOI: 10.1038/sj.bjc.6605099] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
51 Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012;30:1597-1606. [PMID: 21629990 DOI: 10.1007/s10637-011-9691-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
52 Reddy RM, Kakarala M, Wicha MS. Clinical trial design for testing the stem cell model for the prevention and treatment of cancer. Cancers (Basel) 2011;3:2696-708. [PMID: 24212828 DOI: 10.3390/cancers3022696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
53 Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas 2017;46:143-50. [PMID: 28085753 DOI: 10.1097/MPA.0000000000000753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
54 Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008;99:6-13. [PMID: 18577990 DOI: 10.1038/sj.bjc.66 04436] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.Pancreatology. 2020;20:101-109. [PMID: 31787526 DOI: 10.1016/j.pan.2019.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
56 Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials? World J Gastroenterol 2013; 19(8): 1173-1181 [PMID: 23482354 DOI: 10.3748/wjg.v19.i8.1173] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
57 Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017. [PMID: 20876541 DOI: 10.6004/jnccn.2010.0073] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 10.2] [Reference Citation Analysis]
58 Kim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE, Warram JM, Stockard CR, McNally LR, Long JW, Sellers JC, Forero A, Zinn KR. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res 2008;68:8369-76. [PMID: 18922909 DOI: 10.1158/0008-5472.CAN-08-1771] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
59 Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics 2008;2:83-95. [PMID: 19707431 DOI: 10.2147/btt.s1832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 31] [Article Influence: 0.1] [Reference Citation Analysis]
60 Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. [PMID: 24131140 DOI: 10.1056/NEJMoa1304369] [Cited by in Crossref: 3143] [Cited by in F6Publishing: 1689] [Article Influence: 349.2] [Reference Citation Analysis]
61 Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio-Donahue CA. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005;4:548-54. [PMID: 15846069 DOI: 10.4161/cbt.4.5.1663] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 5.5] [Reference Citation Analysis]
62 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 325] [Article Influence: 50.0] [Reference Citation Analysis]
63 Blanco VM, Latif T, Chu Z, Qi X. Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Transl Oncol 2015;8:196-203. [PMID: 26055177 DOI: 10.1016/j.tranon.2015.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
64 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets 2012;13:811-28. [PMID: 22458528 DOI: 10.2174/138945012800564068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
65 Polistina F, Natale GD, Bonciarelli G, Ambrosino G, Frego M. Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol 2014; 20(28): 9374-9383 [PMID: 25071332 DOI: 10.3748/wjg.v20.i28.9374] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
66 Abramson MA, Swanson EW, Whang EE. Surgical resection versus palliative chemoradiotherapy for the management of pancreatic cancer with local venous invasion: a decision analysis. J Gastrointest Surg. 2009;13:26-34. [PMID: 18946644 DOI: 10.1007/s11605-008-0648-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
67 Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 2018;19:e151-60. [PMID: 29508762 DOI: 10.1016/S1470-2045(18)30098-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
68 Starling N, Neoptolemos J, Cunningham D. Role of erlotinib in the management of pancreatic cancer. Ther Clin Risk Manag 2006;2:435-45. [PMID: 18360654 DOI: 10.2147/tcrm.2006.2.4.435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
69 Walsh N, Kennedy S, Larkin A, Corkery B, O’Driscoll L, Clynes M, Crown J, O’Donovan N. EGFR and HER2 inhibition in pancreatic cancer. Invest New Drugs. 2013;31:558-566. [PMID: 23076814 DOI: 10.1007/s10637-012-9891-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
70 Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell’Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer. 2006;94:785-791. [PMID: 16508631 DOI: 10.1038/sj.bjc.6603026] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.4] [Reference Citation Analysis]
71 Zhang S, Xie W, Zou Y, Xie S, Zhang J, Yuan W, Ma J, Zhao J, Zheng C, Chen Y, Wang C. First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis. Cancer Manag Res 2018;10:5965-78. [PMID: 30538546 DOI: 10.2147/CMAR.S162980] [Reference Citation Analysis]
72 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 210] [Cited by in F6Publishing: 198] [Article Influence: 42.0] [Reference Citation Analysis]
73 Plassmeier L, Knoop R, Waldmann J, Kesselring R, Buchholz M, Fichtner-Feigl S, Bartsch DK, Fendrich V. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. Langenbecks Arch Surg. 2013;398:989-996. [PMID: 23989613 DOI: 10.1007/s00423-013-1105-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
74 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72. [DOI: 10.1038/nrclinonc.2009.236] [Cited by in Crossref: 516] [Cited by in F6Publishing: 504] [Article Influence: 43.0] [Reference Citation Analysis]
75 Gupta S, El-Rayes BF. Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics 2008;2:707-15. [PMID: 19707451 DOI: 10.2147/btt.s3003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
76 Rombouts SJ, Nijkamp MW, van Dijck WP, Brosens LA, Konings M, van Hillegersberg R, Borel Rinkes IH, Hagendoorn J, Wittkampf FH, Molenaar IQ. Irreversible Electroporation of the Pancreas Using Parallel Plate Electrodes in a Porcine Model: A Feasibility Study. PLoS One 2017;12:e0169396. [PMID: 28052102 DOI: 10.1371/journal.pone.0169396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
77 Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep 2014;16:388. [PMID: 24740136 DOI: 10.1007/s11912-014-0388-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
78 DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, Vickers SM. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 2007;13:5535s-43s. [PMID: 17875786 DOI: 10.1158/1078-0432.CCR-07-1075] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
79 Knoop RF, Sparn M, Waldmann J, Plassmeier L, Bartsch DK, Lauth M, Hudemann C, Fendrich V. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Neoplasia 2014;16:463-70. [PMID: 24953430 DOI: 10.1016/j.neo.2014.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
80 Oh DY, Lee KW, Lee KH, Sohn CH, Park YS, Zang DY, Ryoo HM, Song HS, Kim JS, Kang HJ, Kim BS, Bang YJ. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Invest New Drugs 2012;30:1164-74. [PMID: 21404106 DOI: 10.1007/s10637-011-9651-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
81 Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Target Oncol 2017;12:309-21. [PMID: 28353074 DOI: 10.1007/s11523-017-0486-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
82 Jones RJ. Cancer stem cells-clinical relevance. J Mol Med (Berl) 2009;87:1105-10. [PMID: 19816664 DOI: 10.1007/s00109-009-0534-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
83 Cavanna L, Stroppa EM, Citterio C, Mordenti P, Di Nunzio C, Peveri S, Orlandi E, Vecchia S. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience. Onco Targets Ther. 2019;12:3077-3085. [PMID: 31118666 DOI: 10.2147/ott.s200754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
84 De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer 2016;16:709. [PMID: 27590845 DOI: 10.1186/s12885-016-2671-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
85 Geng M, Xu H, Ren R, Qu Q, Shangguan C, Wu J, Jiang J, Li H, Cao W. Prognostic value of clinicopathological characteristics in patients with pancreatic cancer. Chin J Cancer Res 2015;27:509-15. [PMID: 26543338 DOI: 10.3978/j.issn.1000-9604.2015.06.03] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
86 Kim EJ, Semrad TJ, Bold RJ. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs. 2015;24:781-794. [PMID: 25809274 DOI: 10.1517/13543784.2015.1026963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
87 Koido S, Homma S, Takahara A, Namiki Y, Tsukinaga S, Mitobe J, Odahara S, Yukawa T, Matsudaira H, Nagatsuma K. Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol. 2011;2011:267539. [PMID: 21922022 DOI: 10.1155/2011/267539] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
88 Mondal G, Almawash S, Chaudhary AK, Mahato RI. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. Mol Pharm 2017;14:3121-33. [PMID: 28719220 DOI: 10.1021/acs.molpharmaceut.7b00355] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
89 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets. 2012;13:811-828. [PMID: 22458528 DOI: 10.1016/j.pestbp.2011.02.012.investigations] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Chen JB, Li JL, He LH, Liu WQ, Yao F, Zeng JY, Zhang Y, Xu KQ, Niu LZ, Zuo JS, Xu KC. Radical treatment of stage IV pancreatic cancer by the combination of cryosurgery and iodine-125 seed implantation. World J Gastroenterol 2012; 18(47): 7056-7062 [PMID: 23323008 DOI: 10.3748/wjg.v18.i47.7056] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
91 Hunsberger S, Zhao Y, Simon R. A comparison of phase II study strategies. Clin Cancer Res 2009;15:5950-5. [PMID: 19789306 DOI: 10.1158/1078-0432.CCR-08-3205] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
92 Marsh Rde W, George T. Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. Curr Gastroenterol Rep 2006;8:111-20. [PMID: 16533473 DOI: 10.1007/s11894-006-0006-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455-1463. [PMID: 18316569 DOI: 10.1158/1078-0432.ccr-07-0371] [Cited by in Crossref: 225] [Cited by in F6Publishing: 152] [Article Influence: 16.1] [Reference Citation Analysis]
94 Lum LG, Thakur A, Choi M, Deol A, Kondadasula V, Schalk D, Fields K, Dufrense M, Philip P, Dyson G, Aon HD, Shields AF. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients. Oncoimmunology 2020;9:1773201. [PMID: 32939319 DOI: 10.1080/2162402X.2020.1773201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
95 Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82. [PMID: 18373843 DOI: 10.1186/1471-2407-8-82] [Cited by in Crossref: 280] [Cited by in F6Publishing: 265] [Article Influence: 20.0] [Reference Citation Analysis]
96 Shah N, Zhai G, Knowles JA, Stockard CR, Grizzle WE, Fineberg N, Zhou T, Zinn KR, Rosenthal EL, Kim H. (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts. Mol Imaging Biol 2012;14:237-44. [PMID: 21494920 DOI: 10.1007/s11307-011-0491-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
97 Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, Satolli MA. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol 2016; 7(1): 27-43 [PMID: 26862489 DOI: 10.5306/wjco.v7.i1.27] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
98 Huang YJ, Frazier ML, Zhang N, Liu Q, Wei C. Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer. Dig Dis Sci 2014;59:968-75. [PMID: 24248418 DOI: 10.1007/s10620-013-2938-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
99 Blomstrand H, Scheibling U, Bratthäll C, Green H, Elander NO. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer 2019;19:40. [PMID: 30621618 DOI: 10.1186/s12885-018-5244-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
100 Stainthorpe A, Greenhalgh J, Bagust A, Richardson M, Boland A, Beale S, Duarte R, Kotas E, Banks L, Palmer D. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 2018;36:1153-63. [PMID: 29600384 DOI: 10.1007/s40273-018-0646-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
101 Sawicka E, Mirończuk A, Wojtukiewicz MZ, Sierko E. Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? Contemp Oncol (Pozn) 2016;20:102-8. [PMID: 27358587 DOI: 10.5114/wo.2016.60066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
102 Furuse J, Gemma A, Ichikawa W, Okusaka T, Seki A, Ishii T. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Jpn J Clin Oncol 2017;47:832-9. [PMID: 28541474 DOI: 10.1093/jjco/hyx075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
103 Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL, Rougier P, Bedenne L, Seitz JF; Fédération Francophone de Cancérologie Digestive. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010;59:1527-34. [PMID: 20947887 DOI: 10.1136/gut.2010.216135] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 4.6] [Reference Citation Analysis]
104 Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem JL. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481-5. [PMID: 16434988 DOI: 10.1038/sj.bjc.6602966] [Cited by in Crossref: 84] [Cited by in F6Publishing: 85] [Article Influence: 5.3] [Reference Citation Analysis]
105 Iancu I, Bartoș A, Cioltean CL, Breazu C, Iancu C, Bartoș D. Role of radio-ablative technique for optimizing the survival of patients with locally advanced pancreatic adenocarcinoma (Review). Exp Ther Med 2021;22:853. [PMID: 34178126 DOI: 10.3892/etm.2021.10285] [Reference Citation Analysis]
106 Lei F, Xi X, Batra SK, Bronich TK. Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer. J Pharmacol Exp Ther 2019;370:682-94. [PMID: 30796131 DOI: 10.1124/jpet.118.255786] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
107 DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. J Gastrointest Surg 2006;10:1291-300; discussion 1300. [PMID: 17114015 DOI: 10.1016/j.gassur.2006.08.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
108 Koutsounas I, Giaginis C, Patsouris E, Theocharis S. Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol 2013; 19(6): 813-828 [PMID: 23430136 DOI: 10.3748/wjg.v19.i6.813] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
109 Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016;7:469-478. [PMID: 27284481 DOI: 10.21037/jgo.2016.01.03] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
110 Williet N, Di Bernardo T, Vernet C, Roche LS, Muron T, Roblin X, Magne N, Phelip JM. Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers. Oncotarget 2018;9:31999-2009. [PMID: 30174792 DOI: 10.18632/oncotarget.25877] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
111 Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, Wang ZH. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Des Devel Ther. 2016;10:1961-1972. [PMID: 27358556 DOI: 10.2147/dddt.s105442] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
112 Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs 2008;26:369-79. [PMID: 18278438 DOI: 10.1007/s10637-008-9123-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
113 Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013;30. [DOI: 10.1007/s12032-012-0361-2] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 8.9] [Reference Citation Analysis]
114 Tate S, Nishikimi K, Matsuoka A, Otsuka S, Kato K, Takahashi Y, Shozu M. Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial. J Gynecol Oncol 2021;32:e8. [PMID: 33185049 DOI: 10.3802/jgo.2021.32.e8] [Reference Citation Analysis]
115 Diehn M, Cho RW, Clarke MF. Therapeutic implications of the cancer stem cell hypothesis. Semin Radiat Oncol. 2009;19:78-86. [PMID: 19249645 DOI: 10.1016/j.semradonc.2008.11.002] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 7.8] [Reference Citation Analysis]
116 Bimonte S, Barbieri A, Leongito M, Piccirillo M, Giudice A, Pivonello C, de Angelis C, Granata V, Palaia R, Izzo F. Curcumin AntiCancer Studies in Pancreatic Cancer. Nutrients 2016;8:E433. [PMID: 27438851 DOI: 10.3390/nu8070433] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
117 Itoi T, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, Kurihara T, Moriyasu F, Tsuchida A, Kasuya K. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol. 2007;42:389-394. [PMID: 17530364 DOI: 10.1007/s00535-007-2017-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.4] [Reference Citation Analysis]
118 Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015; 21(31): 9297-9316 [PMID: 26309356 DOI: 10.3748/wjg.v21.i31.9297] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 74] [Article Influence: 11.9] [Reference Citation Analysis]
119 Liu L, Aleksandrowicz E, Schönsiegel F, Gröner D, Bauer N, Nwaeburu CC, Zhao Z, Gladkich J, Hoppe-Tichy T, Yefenof E, Hackert T, Strobel O, Herr I. Dexamethasone mediates pancreatic cancer progression by glucocorticoid receptor, TGFβ and JNK/AP-1. Cell Death Dis 2017;8:e3064. [PMID: 28981109 DOI: 10.1038/cddis.2017.455] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
120 He C, Wang J, Zhang Y, Cai Z, Lin X, Li S. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation. Cancer Med. 2020;9:4699-4710. [PMID: 32410380 DOI: 10.1002/cam4.3119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
121 Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27:193-198. [PMID: 19047305 DOI: 10.1200/jco.2008.18.9514] [Cited by in Crossref: 187] [Cited by in F6Publishing: 115] [Article Influence: 13.4] [Reference Citation Analysis]
122 Hidalgo M, Abad A, Aranda E, Díez L, Feliu J, Gómez C, Irigoyen A, López R, Rivera F, Rubio C, Sastre J, Tabernero J, Díaz-Rubio E. Consensus on the treatment of pancreatic cancer in Spain. Clin Transl Oncol 2009;11:290-301. [PMID: 19451062 DOI: 10.1007/s12094-009-0357-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
123 Mountzios G, Syrigos KN. A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer. Drug Saf 2011;34:175-86. [PMID: 21332242 DOI: 10.2165/11586540-000000000-00000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
124 Shaib WL, Ip A, Cardona K, Alese OB, Maithel SK, Kooby D, Landry J, El-Rayes BF. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Oncologist 2016;21:178-87. [PMID: 26834159 DOI: 10.1634/theoncologist.2015-0316] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
125 Varghese AM, Lowery MA, Yu KH, O'Reilly EM. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer 2016;122:3765-75. [PMID: 27649047 DOI: 10.1002/cncr.30342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
126 Lawrence B, Findlay M. Systemic therapy for metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol 2010;2:85-106. [PMID: 21789129 DOI: 10.1177/1758834009357188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
127 Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. PLoS One. 2012;7:e38477. [PMID: 22723862 DOI: 10.1371/journal.pone.0038477] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
128 Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison P, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer 2006;94:1107-15. [PMID: 16622436 DOI: 10.1038/sj.bjc.6603058] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
129 Pino MS, Balsamo M, Di Modugno F, Mottolese M, Alessio M, Melucci E, Milella M, McConkey DJ, Philippar U, Gertler FB, Natali PG, Nisticò P. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clin Cancer Res 2008;14:4943-50. [PMID: 18676769 DOI: 10.1158/1078-0432.CCR-08-0436] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
130 Rane JK, Pellacani D, Maitland NJ. Advanced prostate cancer--a case for adjuvant differentiation therapy. Nat Rev Urol 2012;9:595-602. [PMID: 22890299 DOI: 10.1038/nrurol.2012.157] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
131 Wolpin BM, O’Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013;24:1792-1801. [PMID: 23448807 DOI: 10.1093/annonc/mdt066] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
132 Miyatake Y, Kuribayashi-Shigetomi K, Ohta Y, Ikeshita S, Subagyo A, Sueoka K, Kakugo A, Amano M, Takahashi T, Okajima T, Kasahara M. Visualising the dynamics of live pancreatic microtumours self-organised through cell-in-cell invasion. Sci Rep 2018;8:14054. [PMID: 30232338 DOI: 10.1038/s41598-018-32122-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
133 Bittoni A, Santoni M, Lanese A, Pellei C, Andrikou K, Stefano C. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Gastroenterol Res Pract 2014;2014:183852. [PMID: 25101123 DOI: 10.1155/2014/183852] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
134 McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol. 2010;4:404-419. [PMID: 20599450 DOI: 10.1016/j.molonc.2010.06.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 141] [Article Influence: 11.6] [Reference Citation Analysis]
135 Hirooka Y, Kasuya H, Ishikawa T, Kawashima H, Ohno E, Villalobos IB, Naoe Y, Ichinose T, Koyama N, Tanaka M, Kodera Y, Goto H. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer 2018;18:596. [PMID: 29801474 DOI: 10.1186/s12885-018-4453-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
136 Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015;4:1171-1177. [PMID: 25891650 DOI: 10.1002/cam4.459] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
137 Williet N, Petrillo A, Roth G, Ghidini M, Petrova M, Forestier J, Lopez A, Thoor A, Weislinger L, De Vita F, Taieb J, Phelip JM. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Cancers (Basel) 2021;13:2797. [PMID: 34199796 DOI: 10.3390/cancers13112797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
138 Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther 2015;9:3767-77. [PMID: 26244011 DOI: 10.2147/DDDT.S88023] [Cited by in Crossref: 93] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
139 Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 2018;3:CD011044. [PMID: 29557103 DOI: 10.1002/14651858.CD011044.pub2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
140 Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008;99:6-13. [PMID: 18577990 DOI: 10.1038/sj.bjc.6604436] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.0] [Reference Citation Analysis]
141 Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012; 18(35): 4944-4958 [PMID: 23002368 DOI: 10.3748/wjg.v18.i35.4944] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
142 Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. J Gastrointest Cancer 2013;44:182-9. [PMID: 23208490 DOI: 10.1007/s12029-012-9466-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
143 Blomstrand H, Batra A, Cheung WY, Elander NO. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World J Clin Oncol 2021; 12(9): 787-799 [PMID: 34631442 DOI: 10.5306/wjco.v12.i9.787] [Reference Citation Analysis]
144 Amodeo S, Masi A, Melis M, Ryan T, Hochster HS, Cohen DJ, Chandra A, Pachter HL, Newman E. Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. J Gastrointest Oncol 2018;9:922-35. [PMID: 30505595 DOI: 10.21037/jgo.2017.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
145 Fong CYK, Burke E, Cunningham D, Starling N. Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. Gastroenterol Res Pract 2019;2019:7135437. [PMID: 31582971 DOI: 10.1155/2019/7135437] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Sultana A, Ghaneh P, Cunningham D, Starling N, Neoptolemos JP, Smith CT. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer 2008;8:192. [PMID: 18611273 DOI: 10.1186/1471-2407-8-192] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
147 Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer 2014;14:471. [PMID: 24972449 DOI: 10.1186/1471-2407-14-471] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
148 Weng CC, Lin YC, Cheng KH. The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer. J Clin Med 2019;8:E1369. [PMID: 31480737 DOI: 10.3390/jcm8091369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
149 Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 2010; 16(6): 673-682 [PMID: 20135714 DOI: 10.3748/wjg.v16.i6.673] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
150 Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 2006;107:431-4. [PMID: 16150939 DOI: 10.1182/blood-2005-06-2517] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 6.2] [Reference Citation Analysis]
151 Wennier S, Li S, McFadden G. Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med. 2011;13:e18. [PMID: 21676289 DOI: 10.1017/s1462399411001876] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
152 Ko AH. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. Int J Nanomedicine 2016;11:1225-35. [PMID: 27099488 DOI: 10.2147/IJN.S88084] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
153 Pathy S, Chander S. Chemoradiotherapy in pancreatic carcinoma. Indian J Med Paediatr Oncol. 2009;30:55-60. [PMID: 20596304 DOI: 10.4103/0971-5851.60049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.1002/caac.21190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
155 Xu J, Singh A, Amiji MM. Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer. BMC Cancer. 2014;14:75. [PMID: 24507760 DOI: 10.1186/1471-2407-14-75] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
156 Hamada C, Okusaka T, Ikari T, Isayama H, Furuse J, Ishii H, Nakai Y, Imai S, Okamura S. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. Br J Cancer 2017;116:1544-50. [PMID: 28472821 DOI: 10.1038/bjc.2017.128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
157 Cheng HB, Bo Y, Shen WX, Ren XG, Tan JN, Jia ZR, Xu CL. Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedebergs Arch Pharmacol 2015;388:623-34. [PMID: 25743573 DOI: 10.1007/s00210-015-1107-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
158 Ruess DA, Görgülü K, Wörmann SM, Algül H. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs Aging 2017;34:331-57. [PMID: 28349415 DOI: 10.1007/s40266-017-0453-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
159 McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol. 2010;4:404-419. [PMID: 20599450 DOI: 10.1016/j.molonc.2010.06.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, Iacobuzio-Donahue CA. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006;12:2492-2497. [PMID: 16638857 DOI: 10.1158/1078-0432.ccr-05-2655] [Cited by in Crossref: 111] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
161 Rehman H, Chi J, Hakim N, Goyal SP, Olazagasti C, Jose J, Moriarty L, Saif MW. Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer. Therap Adv Gastroenterol 2020;13:1756284820974912. [PMID: 33281939 DOI: 10.1177/1756284820974912] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Sorin V, Ohana P, Gallula J, Birman T, Matouk I, Hubert A, Gilon M, Hochberg A, Czerniak A. H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer. ISRN Oncol. 2012;2012:351750. [PMID: 22701803 DOI: 10.5402/2012/351750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 0.7] [Reference Citation Analysis]
163 Teague A, Lim KH, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol 2015;7:68-84. [PMID: 25755680 DOI: 10.1177/1758834014564775] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 12.3] [Reference Citation Analysis]
164 Mercalli A, Sordi V, Formicola R, Dandrea M, Beghelli S, Scarpa A, Di Carlo V, Reni M, Piemonti L. A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. Br J Cancer 2007;96:1358-67. [PMID: 17426706 DOI: 10.1038/sj.bjc.6603726] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
165 Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908-915. [PMID: 19690548 DOI: 10.1038/sj.bjc.6605256] [Cited by in Crossref: 293] [Cited by in F6Publishing: 239] [Article Influence: 22.5] [Reference Citation Analysis]
166 Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res. 2011;17:2744-2756. [PMID: 21385921 DOI: 10.1158/1078-0432.ccr-10-2214] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
167 Woods NK, Padmanabhan J. Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells. J Biol Chem 2013;288:30114-24. [PMID: 24022491 DOI: 10.1074/jbc.M113.459255] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
168 Gálvez-Peralta M, Dai NT, Loegering DA, Flatten KS, Safgren SL, Wagner JM, Ames MM, Karnitz LM, Kaufmann SH. Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines. Mol Pharmacol 2008;74:724-35. [PMID: 18509065 DOI: 10.1124/mol.108.047787] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
169 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 104] [Article Influence: 17.2] [Reference Citation Analysis]
170 Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. Br J Cancer 2012;106:61-9. [PMID: 22134511 DOI: 10.1038/bjc.2011.526] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
171 Giuliani J, Bonetti A. FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer. Pancreatology 2019;19:325-30. [DOI: 10.1016/j.pan.2019.01.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
172 Walma MS, Rombouts SJ, Brada LJH, Borel Rinkes IH, Bosscha K, Bruijnen RC, Busch OR, Creemers GJ, Daams F, van Dam RM, van Delden OM, Festen S, Ghorbani P, de Groot DJ, de Groot JWB, Haj Mohammad N, van Hillegersberg R, de Hingh IH, D'Hondt M, Kerver ED, van Leeuwen MS, Liem MS, van Lienden KP, Los M, de Meijer VE, Meijerink MR, Mekenkamp LJ, Nio CY, Oulad Abdennabi I, Pando E, Patijn GA, Polée MB, Pruijt JF, Roeyen G, Ropela JA, Stommel MWJ, de Vos-Geelen J, de Vries JJ, van der Waal EM, Wessels FJ, Wilmink JW, van Santvoort HC, Besselink MG, Molenaar IQ; Dutch Pancreatic Cancer Group. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial. Trials 2021;22:313. [PMID: 33926539 DOI: 10.1186/s13063-021-05248-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Kanai M. Therapeutic applications of curcumin for patients with pancreatic cancer. World J Gastroenterol 2014; 20(28): 9384-9391 [PMID: 25071333 DOI: 10.3748/wjg.v20.i28.9384] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
174 Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T. Survival prediction for pancreatic cancer patients receiving gemcitabine treatment. Mol Cell Proteomics 2010;9:695-704. [PMID: 20061307 DOI: 10.1074/mcp.M900234-MCP200] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
175 Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82. [PMID: 18373843 DOI: 10.1186/11471-2407-8-82] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Bridgewater J, Lopes A, Palmer D, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Valle J, Wasan H. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer 2016;114:965-71. [PMID: 27115567 DOI: 10.1038/bjc.2016.64] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
177 Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 2011;103:1093-100. [PMID: 21709274 DOI: 10.1093/jnci/djr218] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
178 Awasthi N, Kirane A, Schwarz MA, Toombs JE, Brekken RA, Schwarz RE. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. BMC Cancer 2011;11:15. [PMID: 21226944 DOI: 10.1186/1471-2407-11-15] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
179 Brunner TB, Scott-Brown M. The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol. 2010;5:64. [PMID: 20615227 DOI: 10.1186/1748-717x-5-64] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
180 Hu J, Zhao G, Wang HX, Tang L, Xu YC, Ma Y, Zhang FC. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 2011;4:11. [PMID: 21439076 DOI: 10.1186/1756-8722-4-11] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
181 Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012; 18(33): 4533-4541 [PMID: 22969226 DOI: 10.3748/wjg.v18.i33.4533] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
182 He J, Page AJ, Weiss M, Wolfgang CL, Herman JM, Pawlik TM. Management of borderline and locally advanced pancreatic cancer: Where do we stand? World J Gastroenterol 2014; 20(9): 2255-2266 [PMID: 24605025 DOI: 10.3748/wjg.v20.i9.2255] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
183 Kim H, Zhai G, Liu Z, Samuel S, Shah N, Helman EE, Knowles JA, Stockard CR, Fineberg NS, Grizzle WE, Zhou T, Zinn KR, Rosenthal EL. Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anticancer Drugs 2011;22:864-74. [PMID: 21730821 DOI: 10.1097/CAD.0b013e328349311e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
184 Forero-Torres A, Infante JR, Waterhouse D, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, von Roemeling R, Greenberg J, Saleh M. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Med 2013;2:925-32. [PMID: 24403266 DOI: 10.1002/cam4.137] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
185 Jones RJ, Matsui W. Cancer Stem Cells: From Bench to Bedside. Biol Blood Marrow Transplant 2007;13:47-52. [PMID: 18167509 DOI: 10.1016/j.bbmt.2006.10.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
186 Lomberk GA, Urrutia R. The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure. Surg Clin North Am. 2015;95:935-952. [PMID: 26315515 DOI: 10.1016/j.suc.2015.05.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
187 Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M, Shapiro J, Davies T, Reece W, Harvey J, Spry N. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 2007;97:464-71. [PMID: 17653074 DOI: 10.1038/sj.bjc.6603900] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
188 Paiella S, Salvia R, Ramera M, Girelli R, Frigerio I, Giardino A, Allegrini V, Bassi C. Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review. Gastroenterol Res Pract. 2016;2016:4508376. [PMID: 26981115 DOI: 10.1155/2016/4508376] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 6.7] [Reference Citation Analysis]